Literature DB >> 15905610

Development of a monoclonal antibody against Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) that can detect EBNA-LP expressed in P3HR1 cells.

Fumio Shaku1, Go Matsuda, Rie Furuya, Chinatsu Kamagata, Mie Igarashi, Michiko Tanaka, Mikiko Kanamori, Yukihiro Nishiyama, Naoki Yamamoto, Yasushi Kawaguchi.   

Abstract

A mouse monoclonal antibody, LP4D3, was raised against purified Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) fused to glutathione-S-transferase. The antibody detected endogenous and exogenous EBNA-LP in immunoblotting, immunofluorescence and immunoprecipitation assays, and the epitope of the antibody was mapped in the W2 domain of EBNA-LP. While another monoclonal antibody to EBNA-LP, JF186, which is widely used for analyses of the viral protein, did not react with truncated forms of EBNA-LP expressed in P3HR1 cells, as reported earlier, the LP4D3 antibody did. The LP4D3 antibody will be a useful tool for further studies of EBNA-LP, especially investigations into the phenotypes of mutant EBNA-LP expressed in P3HR1 cells.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15905610     DOI： 10.1111/j.1348-0421.2005.tb03743.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN： 0385-5600            Impact factor:   1.955


  7 in total

1.  Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A.

Authors:  Julie Garibal; Emilie Hollville; Andrew I Bell; Gemma L Kelly; Benjamin Renouf; Yasushi Kawaguchi; Alan B Rickinson; Joëlle Wiels
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

2.  Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1.

Authors:  Ami Watanabe; Seiji Maruo; Taku Ito; Miho Ito; Koichi Ricardo Katsumura; Kenzo Takada
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

3.  Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines.

Authors:  Lenka Skalska; Robert E White; Gillian A Parker; Ernest Turro; Alison J Sinclair; Kostas Paschos; Martin J Allday
Journal:  PLoS Pathog       Date:  2013-02-21       Impact factor: 6.823

4.  C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Authors:  Laila Cancian; Rachel Bosshard; Walter Lucchesi; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

5.  New Interactors of the Truncated EBNA-LP Protein Identified by Mass Spectrometry in P3HR1 Burkitt's Lymphoma Cells.

Authors:  Sonia Chelouah; Emilie Cochet; Sophie Couvé; Sandy Balkaran; Aude Robert; Evelyne May; Vasily Ogryzko; Joëlle Wiels
Journal:  Cancers (Basel)       Date:  2018-01-05       Impact factor: 6.639

6.  Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome.

Authors:  Agnieszka Szymula; Richard D Palermo; Amr Bayoumy; Ian J Groves; Mohammed Ba Abdullah; Beth Holder; Robert E White
Journal:  PLoS Pathog       Date:  2018-02-20       Impact factor: 6.823

7.  Heterogeneity of the Epstein-Barr Virus (EBV) Major Internal Repeat Reveals Evolutionary Mechanisms of EBV and a Functional Defect in the Prototype EBV Strain B95-8.

Authors:  Mohammed M Ba Abdullah; Richard D Palermo; Anne L Palser; Nicholas E Grayson; Paul Kellam; Samantha Correia; Agnieszka Szymula; Robert E White
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.